Roche in talks to buy Roivant Sciences drug for $7 billion, reveals The Wall Street Journal

Hacks at The Wall Street Journal landed a decent scoop overnight about Switzerland's Roche talks to buy a stomach drug from Roivant Sciences, the US-listed biotechnology group.

You need to register and sign in to read this content.